Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Discontinuing PJP prophylaxis while on prednisone doses greater than 12.5 mg per day may elevate infection risk among patients with rheumatic diseases.

Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

A low dose combination hormonal patch was found to be effective for pregnancy prevention based on results from a phase 3 study.

Use of a combined oral contraceptive (COC) is not associated with asthma in women of reproductive age, but use of a progestogen-only pill (POP) is associated with an increased risk for asthma attacks ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.